Trial Profile
Phase II study of capecitabine and oxaliplatin (XELOX) in patients with locally advanced, incurable, salivary gland cancers
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Mar 2017
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Oxaliplatin (Primary)
- Indications Salivary gland cancer
- Focus Therapeutic Use
- 15 Aug 2005 New trial record.